Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Idiopathic intracranial hypertension associated with depot medroxyprogesterone

Sir,

Many associations of idiopathic intracranial hypertension (IIH) with various medications have not been well substantiated. Adequate proof of association requires that withdrawal of the medication decrease the CSF pressure in patients with IIH. This report describes a 23-year-old woman, who developed IIH after using depot medroxyprogesterone acetate and experienced total resolution of IIH after discontinuation of this medication.

Case report

A 23-year-old woman with a body mass index of 28.2 kg/m2 presented with a 3-week history of retro-orbital pain and headaches associated with horizontal diplopia, photopsias, tinnitus, and nausea. Her past medical and family histories were unremarkable. Her only medication was contraception with depot medroxyprogesterone acetate (Depo Provera), which she had taken only one dose 2 months ago.

Her visual acuity was 20/20 OU with a right absolute central scotoma. Pupillary responses and color vision were normal. She had a 10 prism diopter right esotropia. Tonometry revealed 17 mmHg OU. Anterior segment examination was normal. She had bilateral papilloedema with nerve fibre layer haemorrhages in the superior peripapillary regions OD and punctate haemorrhages in the medial inferior peripapillary regions OD. No macular star was present.

MRI of the brain and orbits with and without contrast and MR venogram were normal. Her CSF opening pressure was elevated at 520 mm H2O. CSF protein, glucose, cell count, VDRL, Gram stain, acid fast bacilli stain; routine bacterial, viral, and fungal cultures; and cytology were all normal. Laboratories including complete blood count with platelets, chemistry panel, liver function tests, PT/PTT/INR, sedimentation rate, antinuclear antibodies, RPR, VDRL, rheumatoid factor, and angiotensin-converting enzyme were normal. Other autoimmune disorders were ruled out with negative anti-double-stranded DNA, anti-SSA, anti-SSB, anti-Ro, and anti-Jo1 antibodies. Laboratory investigation, including protein C and S, antiphospholipid, anticardiolipin, and antiphosphatidylserine antibodies, did not reveal a hypercoagulable state. T3, T4, thyroid stimulating hormone, and antithyroglobulin antibodies were also normal. Urine beta human chorionic gonadotropin test was negative.

After developing IIH, she elected to discontinue this medication and not take any further ones, including carbonic anhydrase inhibitors or corticosteroids for the treatment of her IIH. After the fourth monthly visit, she had total resolution of her papilloedema and related symptoms. Repeat lumbar puncture revealed a decreased CSF opening pressure of 131 mm H2O. Her body mass index remained the same.

Comment

Several reports have described IIH after standard oral contraceptives, containing 20–30 μg of ethinyl estradiol (EE) and after emergency contraception with 200 μg for EE over 2 days.1 Unlike levonorgestrel implants,2, 3 medroxyprogesterone acetate has not been clearly associated with IIH. Only one report in the literature describes a 29-year-old woman who developed IIH 8 weeks after an injection of medroxyprogesterone acetate and received oral dexamethasone without follow-up data regarding resolution of her symptoms after withdrawal of medroxyprogesterone.4

This report demonstrates more convincing evidence linking depot medroxyprogesterone acetate with the development of IIH. Withdrawal of this medication in the patient resulted in complete resolution of IIH, as evidenced by a normal neuro-ophthalmic examination and a CSF opening pressure of 131 mm H2O after 4 months. This wash-out period is consistent with the half-life of the medication. The serum level from a recommended dose of medroxyprogesterone 150 mg intramuscularly usually increases over 3 weeks to reach peak plasma concentrations between 1 and 7 ng/ml. The levels then exponentially decrease until they become undetectable (<100 pg/ml) between 120 to 200 days following injection.5

The close temporal relationship between the use of medroxyprogesterone acetate and development of IIH, and the resolution of IIH after medication withdrawal are only suggestive of a causal relationship. The exact pathogenesis of IIH from progestins remains unclear. Increased awareness of this adverse effect is important, as more women are using this medication for contraception and for menstrual irregularities because of its more convenient dosing of once every 12–13 weeks and its lower cost compared to oral contraceptives.

References

  1. Ivancic R, Pfadenhauer K . Pseudotumor cerebri after hormonal emergency contraception. Eur Neurol 2004; 52: 120.

    CAS  Article  Google Scholar 

  2. Alder JB, Fraunfelder FT, Edwards R . Levonorgestrel implants and intracranial hypertension. N Engl J Med 1995; 332: 1720–1721.

    CAS  Article  Google Scholar 

  3. Wyskowski DK, Green L . Serious adverse events in Norplant users reported to the Food and Drug Administration. Obstet Gynecol 1995; 85: 538–542.

    Article  Google Scholar 

  4. Bahemuka M . Benign intracranial hypertension associated with the use of Depo-Porvera (depot medroxyprogesterone): a case report. East Afr Med J. 1981; 58 (2): 140–141.

    CAS  PubMed  Google Scholar 

  5. Westhoff C . Depot-medroxyprogesterone acetate injection (Depo-Provera): a highly effective contraceptive option with proven long-term safety. Contraception. 2003; 68 (2): 75–87.

    CAS  Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J W Chan.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Chan, J. Idiopathic intracranial hypertension associated with depot medroxyprogesterone. Eye 20, 1396–1397 (2006). https://doi.org/10.1038/sj.eye.6702245

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.eye.6702245

Further reading

Search

Quick links